Acrux Ltd has released a press release.
Acrux has second generic dossier accepted for review by FDA
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Acrux
- Acrux confirms patent challenge for generic of efinaconazole
- Appendix 4E and 2018 Financial Report
- Acrux Submits First-To-File Generic of Jublia
- Appendix 4D and Half-Year Report to 31 December 2017
- Axiron Net Sales Quarter to December 2017
Later from Acrux
- Acrux Receives $2.057m R&D Tax Incentive Rebate
- Appendix 4D and Half-Year Financial Report to 31 Dec 2018
- Jublia Patent Litigation Settlement
- Appendix 4E & Full Year Statutory Accounts
- Acrux Ltd Investor Presentation and Full Year Results
Follow Acrux into a list and get an email when it puts out news.
Follow Acrux